• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form POS AM filed by TriSalus Life Sciences Inc.

    11/6/24 4:30:05 PM ET
    $TLSI
    Medical Specialities
    Health Care
    Get the next $TLSI alert in real time by email
    POS AM 1 tm2427627d1_posam.htm POS AM

     

    As filed with the U.S. Securities and Exchange Commission on November 6, 2024.

     Registration No. 333-276070

     

     

    UNITED STATES 

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    POST-EFFECTIVE AMENDMENT NO. 3

    TO

     

    FORM S-1 

    on

    FORM S-3

     

    REGISTRATION STATEMENT 

    UNDER

    THE SECURITIES ACT OF 1933

     

    TRISALUS LIFE SCIENCES, INC. 

    (Exact name of registrant as specified in its charter)

     

    Delaware

    (State or other jurisdiction of
    incorporation or organization)

     

    3841

    (Primary Standard Industrial
    Classification Code Number)

     

    85-3009869

    (I.R.S. Employer
    Identification No.)

     

    6272 W. 91st Ave.

    Westminster, Colorado 80031 

    (888) 321-5212

    (Address, including zip code, and telephone number, including area code, of registrant’s principal executive offices)

     

    Mary Szela 

    Chief Executive Officer

    6272 W. 91st Ave. 

    Westminster, Colorado 80031

    (888) 321-5212 

    (Name, address, including zip code, and telephone number, including area code, of agent for service)

     

    Copy to:

    Matt Browne 

    Carlos Ramirez

    Cooley LLP 

    10265 Science Center Dr

    San Diego, California 92121 

    (858) 550-6000

     

    Approximate date of commencement of proposed sale to the public:

    From time to time on or after this registration statement is declared effective.

     

    If the only securities being registered on this Form are being offered pursuant to dividend or interest reinvestment plans, please check the following box: ¨

     

    If any of the securities being registered on this Form are to be offered on a delayed or continuous basis pursuant to Rule 415 under the Securities Act of 1933, other than securities offered only in connection with dividend or interest reinvestment plans, check the following box. x

     

    If this Form is filed to register additional securities for an offering pursuant to Rule 462(b) under the Securities Act, please check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering.  ¨

     

    If this Form is a post-effective amendment filed pursuant to Rule 462(c) under the Securities Act, check the following box and list the Securities Act registration statement number of the earlier effective registration statement for the same offering. ¨

     

    If this Form is a registration statement pursuant to General Instruction I.D. or a post-effective amendment thereto that shall become effective upon filing with the Commission pursuant to Rule 462(e) under the Securities Act, check the following box.  ¨

     

    If this Form is a post-effective amendment to a registration statement filed pursuant to General Instruction I.D. filed to register additional securities or additional classes of securities pursuant to Rule 413(b) under the Securities Act, check the following box.  ¨

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

           
    Large accelerated filer ¨ Accelerated filer ¨
    Non-accelerated filer x Smaller reporting company x
        Emerging growth company x

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

    This post-effective amendment will become effective in accordance with the provisions of Section 8(c) of the Securities Act of 1933, as amended.

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Post-Effective Amendment No. 3 to the Registration Statement on Form S-1 on Form S-3 (File No.333-276070) (the “Registration Statement”) is being filed solely to amend the Post-Effective Amendment No. 2 to the Registration Statement filed with the U.S. Securities and Exchange Commission on October 29, 2024, to add Exhibit 10.1 to the Exhibit Index set forth in Part II. Item 16(a) hereto. This Post-Effective Amendment No. 3 does not modify any provision of the prospectus that forms part of the Registration Statement and, accordingly, the prospectus has not been included herein. This Post-Effective Amendment No. 3 is not intended to amend or delete any part of the Registration Statement except as specifically noted herein.

     

    1

     

     

    PART II

     

    INFORMATION NOT REQUIRED IN PROSPECTUS

     

    Item 16. Exhibits and Financial Statement Schedules.

     

    (a)Exhibits.

     

    The exhibits listed below are filed as part of this registration statement.

     

            Incorporated by Reference
    Exhibit   Description   Schedule/
    Form
      File Number   Exhibits   Filing Date
    2.1†**   Agreement and Plan of Merger, dated as of November 11, 2022, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc.   Form 8-K   001-39813   2.1   November 14, 2022
    2.2**   First Amendment to Agreement and Plan of Merger, dated as of April 4, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc.   Form 8-K   001-39813   10.1   April 5, 2023
    2.3**   Second Amendment to Agreement and Plan of Merger, dated as of May 13, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc.   Form 8-K   001-39813   10.1   May 15, 2023
    2.4**   Third Amendment to Agreement and Plan of Merger, dated as of July 5, 2023, by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc., and TriSalus Life Sciences, Inc.   Form 8-K   001-39813   10.1   July 6, 2023
    4.1**   Second Amended and Restated Certificate of Incorporation of TriSalus Life Sciences, Inc.   Form 8-K   001-39813   3.1   August 16, 2023
    4.2**   Amended and Restated Bylaws of TriSalus Life Sciences, Inc.   Form 8-K   001-39813   3.2   August 16, 2023
    4.3**   Form of Certificate of Designations, Preferences and Rights of Series A Convertible Preferred Stock of TriSalus Life Sciences, Inc.   Form 8-K   001-39813   3.3   August 16, 2023
    4.4**   Specimen Common Stock Certificate.   Form 8-K   001-39813   4.1   August 16, 2023
    4.5**   Specimen Warrant Certificate.   Form 8-K   001-39813   4.2   August 16, 2023
    4.6**   Warrant Agreement, dated December 17, 2020, by and between MTAC and Continental Stock Transfer & Trust Company.   Form 8-K   001-39813   4.1   December 23, 2020
    4.7**   Form of Amended and Restated Registration Rights Agreement, by and among TriSalus Life Sciences, Inc., MedTech Acquisition Sponsor LLC, and certain former stockholders of TriSalus Life Sciences, Inc.   Form 8-K   001-39813   10.1   November 14, 2022
    4.8**   Registration Rights Agreement, dated April 30, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP.   Form 10-Q   001-39813   4.4   May 15, 2024
    4.9**   Amendment No. 1 to Warrant Agreement, dated June 26, 2024, by and between the Company and Continental Stock Transfer & Trust Company.   Form 8-K   001-39813   10.1   June 27, 2024
    4.10**   Substitute Warrant Certificate, August 15, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV, LP.   Form S-1   333-276070   4.10   October 29, 2024

     

    2

     

     

            Incorporated by Reference
    Exhibit   Description   Schedule/
    Form
      File Number   Exhibits   Filing Date
    4.11**   Substitute Warrant Certificate, dated August 15, 2024, by and between TriSalus Life Sciences, Inc., and OrbiMed Royalty & Credit Opportunities IV Offshore, LP.   Form S-1   333-276070   4.11   October 29, 2024
    5.1**   Opinion of Cooley LLP.   Form S-1   333-276070   5.1   December 15, 2023
    10.1**   Standby Equity Purchase Agreement, by and between the TriSalus Life Sciences, Inc. and YA II PN, LTD.   Form 8-K   001-39813   99.1   October 3, 2023
    23.1**   Consent of KPMG LLP, independent registered public accounting firm.   Form S-1   333-276070   23.1   October 29, 2024
    23.2**   Consent of Cooley LLP (included in Exhibit 5.1).   Form S-1   333-276070   5.1   December 15, 2023
    24.1**   Power of Attorney (included on signature page of S-1).   Form S-1   333-276070   24.1   December 15, 2023
    24.2**   Power of Attorney.                
    107**   Filing Fee Table.   Form S-1   333-276070   107   December 15, 2023

     

    *Filed herewith.

     

    **Previously filed.

     

    †Certain of the exhibits and schedules to this Exhibit have been omitted in accordance with Regulation S-K Item 601(a)(5). The Registrant agrees to furnish a copy of all omitted exhibits and schedules to the SEC upon its request; provided, however, that the Registrant may request confidential treatment pursuant to Rule 24b-2 of the Exchange Act, as amended, for any schedule or exhibit so furnished.

     

    3

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the Company has duly caused this Post-Effective Amendment No.3 to registration statement on Form S-1 on Form S-3 to be signed on its behalf by the undersigned, thereunto duly authorized in the City of Westminster, State of Colorado, on this 6th day of November, 2024.

     

      TRISALUS LIFE SCIENCES, INC.
       
      By: /s/ Mary Szela
        Mary Szela
        Chief Executive Officer

     

    Pursuant to the requirements of the Securities Act of 1933, this Post-Effective Amendment No. 3 to registration statement on Form S-1 on Form S-3 has been signed by the following persons in the capacities and on the dates indicated.

     

    /s/ Mary Szela   Chief Executive Officer and Director   November 6, 2024
    Mary Szela   (Principal Executive Officer)    
             
    /s/ Sean Murphy   Chief Financial Officer and Director   November 6, 2024
    Sean Murphy   (Principal Financial and Accounting Officer)    
             
    *   Chairman   November 6, 2024
    Mats Wahlström        
             
    *   Director   November 6, 2024
    Arjun “JJ” Desai        
             
    *   Director   November 6, 2024
    Andrew von Eschenbach        
             
    *   Director   November 6, 2024
    Kerry Hicks        
             
    *   Director   November 6, 2024
    Liselotte Hyveled        
             
    *   Director   November 6, 2024
    George Kelly Martin        
             
    *   Director   November 6, 2024
    David J. Matlin        

     

           
    * By: /s/ Mary Szela        
     

    Mary Szela

    Attorney-in-Fact

           

     

     

    4

     

    Get the next $TLSI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $TLSI

    DatePrice TargetRatingAnalyst
    2/13/2025Buy
    Lake Street
    12/17/2024$10.00Overweight
    Cantor Fitzgerald
    11/11/2024$11.00Buy
    ROTH MKM
    10/25/2024$12.50Outperform
    Northland Capital
    9/16/2024$10.00Outperform
    Oppenheimer
    5/30/2024$12.00Buy
    Canaccord Genuity
    More analyst ratings

    $TLSI
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun "JJ" Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board expressed their sincere appreciation for Dr. Desai's service and contributions during his tenure. Concurrently, TriSalus announced that Michael P. Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026

    2/9/26 9:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

    Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance Set initial 2026 revenue guidance of approximately $60-$62 million TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and full-year

    1/12/26 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Symptomatic Thyroid Disease on December 15, 2025

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Monday, December 15, 2025 at 2:00 PM ET featuring Juan C. Camacho, MD (Florida State University), who will join company management to discuss the unmet need and current treatment landscape for symptomatic thyroid disease. To register, click here. The event will provide an overview of the TriNav Infusion System and its Pressure-Enabled Delivery for Thyroid Artery Embolization (PED-TAE) approach. PED

    12/4/25 4:01:00 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Financial Officer Young James Emmett bought $33,900 worth of shares (6,000 units at $5.65) (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/6/25 6:09:01 PM ET
    $TLSI
    Medical Specialities
    Health Care

    CEO AND PRESIDENT Szela Mary T bought $51,754 worth of shares (10,040 units at $5.15), increasing direct ownership by 2% to 444,259 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    1/31/25 5:54:39 PM ET
    $TLSI
    Medical Specialities
    Health Care

    CEO AND PRESIDENT Szela Mary T was granted 40,000 shares and bought $50,303 worth of shares (9,542 units at $5.27), increasing direct ownership by 13% to 434,219 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    1/29/25 6:15:05 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lake Street initiated coverage on TriSalus Life Sciences

    Lake Street initiated coverage of TriSalus Life Sciences with a rating of Buy

    2/13/25 8:48:50 AM ET
    $TLSI
    Medical Specialities
    Health Care

    Cantor Fitzgerald initiated coverage on TriSalus Life Sciences with a new price target

    Cantor Fitzgerald initiated coverage of TriSalus Life Sciences with a rating of Overweight and set a new price target of $10.00

    12/17/24 8:31:30 AM ET
    $TLSI
    Medical Specialities
    Health Care

    ROTH MKM initiated coverage on TriSalus Life Sciences with a new price target

    ROTH MKM initiated coverage of TriSalus Life Sciences with a rating of Buy and set a new price target of $11.00

    11/11/24 7:48:55 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 4 filed by Director Stansky Michael P

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/11/26 6:51:12 PM ET
    $TLSI
    Medical Specialities
    Health Care

    New insider Stansky Michael P claimed ownership of 625,732 shares (SEC Form 3)

    3 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    2/11/26 6:50:03 PM ET
    $TLSI
    Medical Specialities
    Health Care

    Chief of Research Cox Bryan F. was granted 40,000 shares, increasing direct ownership by 32% to 166,599 units (SEC Form 4)

    4 - TriSalus Life Sciences, Inc. (0001826667) (Issuer)

    11/25/25 4:15:56 PM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    SEC Filings

    View All

    TriSalus Life Sciences Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    2/9/26 8:59:49 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    1/12/26 7:09:19 AM ET
    $TLSI
    Medical Specialities
    Health Care

    SEC Form EFFECT filed by TriSalus Life Sciences Inc.

    EFFECT - TriSalus Life Sciences, Inc. (0001826667) (Filer)

    12/5/25 12:15:29 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Financials

    Live finance-specific insights

    View All

    TriSalus Life Sciences Announces Preliminary Fourth Quarter and Full-Year 2025 Results and 2026 Revenue Guidance

    Fourth quarter 2025 revenue of approximately $13.2 million, Up 60% Year-Over-Year Full-year 2025 revenue growth of approximately 53% exceeded 2025 guidance Set initial 2026 revenue guidance of approximately $60-$62 million TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today reported preliminary unaudited financial results for the fourth quarter and full year ended December 31, 2025. The Company anticipates fourth quarter 2025 revenues of approximately $13.2 million and full-year

    1/12/26 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Reports Third Quarter 2025 Results and Reaffirms 2025 Revenue Guidance

    TriSalus Reports $11.6 million in Revenue, Up 57% Year-over-Year, Reflecting Strong Liver Embolization growth Investigator Published Data Show TriNav Enables Safe, Effective Thyroid Embolization Alternative to Surgery Reaffirmed revenue guidance of at least 50% growth due to continued commercial momentum Hosting Conference Call and Webcast today at 4:30pm ET TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces financial results for the quarter ended September 30, 2025, and pr

    11/13/25 4:01:00 PM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences to Host Third Quarter 2025 Financial Results Conference Call

    Conference Call and Webcast Scheduled for Thursday November 13, 2025 at 4:30 PM TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a conference call and webcast on Thursday November 13, 2025 at 4:30 PM eastern time to discuss its financial results for the quarter ended September 30, 2025. A press release detailing the results will be issued prior to the call. Parties interested in participating by phone should register using this online form. After registering for the webcast, dial-in det

    10/30/25 8:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Leadership Updates

    Live Leadership Updates

    View All

    TriSalus Life Sciences Appoints Veteran Healthcare Investor Michael Stansky to its Board of Directors

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology-focused medical technology company advancing novel drug delivery technologies alongside standard-of-care therapies to improve outcomes for patients with solid tumors, today announced changes to its Board of Directors. TriSalus announced that Dr. Arjun "JJ" Desai, a member of the Board since August of 2023, has elected to resign from the Board. The Company and the Board expressed their sincere appreciation for Dr. Desai's service and contributions during his tenure. Concurrently, TriSalus announced that Michael P. Stansky has been appointed to the Company's Board of Directors, effective February 4, 2026

    2/9/26 9:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences to Host Virtual KOL Event to Discuss the TriNav Infusion System for the Treatment of Uterine Fibroids on November 12, 2025

    TriSalus Life Sciences, Inc. (NASDAQ:TLSI) ("TriSalus" or the "Company"), an oncology company integrating novel delivery technology with standard of care therapies to transform treatment for patients with solid tumors, announced today that it will host a virtual key opinion leader (KOL) event on Wednesday, November 12, 2025 at 10:00 AM ET featuring Nicole Lamparello, MD (Weill Cornell Medicine, New York-Presbyterian Hospital) and Francis Kang, MD (University Radiology Group, Rutgers Robert Wood Johnson University Hospital), who will join company management to discuss the unmet need and current treatment landscape for uterine fibroids. To register, click here. The event will provide an over

    11/10/25 8:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    TriSalus Life Sciences Announces Chief Financial Officer Transition With Appointment of David B. Patience

    David Patience, an accomplished healthcare CFO with deep experience in the life sciences sector, appointed as CFO effective July 1, 2025 Current CFO James E. Young steps down; Dan Giordano, Vice President of Finance, to serve as acting CFO during transition period TriSalus Life Sciences, Inc. (NASDAQ:TLSI) (the "Company"), an oncology company integrating novel delivery technology with standard of care therapies and its investigational immunotherapeutic to transform treatment for patients with solid tumors, today announces the appointment of David B. Patience as Chief Financial Officer, effective July 1, 2025. Mr. Patience succeeds James Young, who stepped down for personal reasons effec

    5/30/25 7:00:00 AM ET
    $TLSI
    Medical Specialities
    Health Care

    $TLSI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    12/4/24 4:00:06 PM ET
    $TLSI
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by TriSalus Life Sciences Inc.

    SC 13G - TriSalus Life Sciences, Inc. (0001826667) (Subject)

    10/21/24 8:25:05 AM ET
    $TLSI
    Medical Specialities
    Health Care